These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34709816)

  • 21. PROTAC-DB 3.0: an updated database of PROTACs with extended pharmacokinetic parameters.
    Ge J; Li S; Weng G; Wang H; Fang M; Sun H; Deng Y; Hsieh CY; Li D; Hou T
    Nucleic Acids Res; 2024 Sep; ():. PubMed ID: 39225044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elucidation of Genome-wide Understudied Proteins targeted by PROTAC-induced degradation using Interpretable Machine Learning.
    Xie L; Xie L
    bioRxiv; 2023 Feb; ():. PubMed ID: 36865212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Computational methods and key considerations for in silico design of proteolysis targeting chimera (PROTACs).
    Abbas A; Ye F
    Int J Biol Macromol; 2024 Oct; 277(Pt 4):134293. PubMed ID: 39084437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
    Li X; Song Y
    J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An In Vitro Pull-down Assay of the E3 Ligase:PROTAC:Substrate Ternary Complex to Identify Effective PROTACs.
    Bondeson DP; Smith BE; Buhimschi AD
    Methods Mol Biol; 2021; 2365():135-150. PubMed ID: 34432242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanistic and Structural Features of PROTAC Ternary Complexes.
    Casement R; Bond A; Craigon C; Ciulli A
    Methods Mol Biol; 2021; 2365():79-113. PubMed ID: 34432240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
    Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
    Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In Silico Modeling and Scoring of PROTAC-Mediated Ternary Complex Poses.
    Liao J; Nie X; Unarta IC; Ericksen SS; Tang W
    J Med Chem; 2022 Apr; 65(8):6116-6132. PubMed ID: 35412837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monitoring and deciphering protein degradation pathways inside cells.
    Daniels DL; Riching KM; Urh M
    Drug Discov Today Technol; 2019 Apr; 31():61-68. PubMed ID: 31200861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. General Stepwise Approach to Optimize a TR-FRET Assay for Characterizing the BRD/PROTAC/CRBN Ternary Complex.
    Lin W; Chen T
    ACS Pharmacol Transl Sci; 2021 Apr; 4(2):941-952. PubMed ID: 33860212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.
    Li R; Liu M; Yang Z; Li J; Gao Y; Tan R
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36557960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DegraderTCM: A Computationally Sparing Approach for Predicting Ternary Degradation Complexes.
    Rossetti P; Apprato G; Caron G; Ermondi G; Rossi Sebastiano M
    ACS Med Chem Lett; 2024 Jan; 15(1):45-53. PubMed ID: 38229751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A close-up shot of protein-protein docking, from experiment to theory and reverse with the PROTAC performers.
    Nguyen KQT; Nguyen HH; Phung HTT; Chung KL; Vu TY
    J Biomol Struct Dyn; 2024 Jan; ():1-8. PubMed ID: 38284361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interplay of PROTAC Complex Dynamics for Undruggable Targets: Insights into Ternary Complex Behavior and Linker Design.
    Kumar H; Sobhia ME
    ACS Med Chem Lett; 2024 Aug; 15(8):1306-1318. PubMed ID: 39140051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation.
    Chen Y; Tandon I; Heelan W; Wang Y; Tang W; Hu Q
    Chem Soc Rev; 2022 Jul; 51(13):5330-5350. PubMed ID: 35713468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
    Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
    Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Native Mass Spectrometry Can Effectively Predict PROTAC Efficacy.
    Beveridge R; Kessler D; Rumpel K; Ettmayer P; Meinhart A; Clausen T
    ACS Cent Sci; 2020 Jul; 6(7):1223-1230. PubMed ID: 32724856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
    Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
    Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced protein degradation by intracellular delivery of pre-fused PROTACs using lipid-like nanoparticles.
    Chen J; Qiu M; Ma F; Yang L; Glass Z; Xu Q
    J Control Release; 2021 Feb; 330():1244-1249. PubMed ID: 33234362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Native mass spectrometry interrogation of complexes formed during targeted protein degradation.
    Ahmed IMM; Beveridge R
    Rapid Commun Mass Spectrom; 2023 Nov; 37(22):e9604. PubMed ID: 37817340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.